Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AAC, advocacy, Aevi, Africa, AHA, Albunorm, Alexion, analogue, annuity, antidilutive, APAC, aPCC, ASOCOL, aspirational, ASPIRO, attempting, Avid, Avrobio, awaiting, bag, Baggot, banning, begun, Biomarin, Bioverativ, Bioveritiv, Booz, bottom, bradykinin, British, buccally, Busch, Buyout, chart, checkpoint, CHF, Chicago, CHMP, CIC, clinician, CNP, compensatory, constantly, consumption, copay, Cordeiro, crucial, cTTP, delisting, Dell, dialog, disaggregate, Dittrich, divisional, drove, Dublin, dynamic, empirical, engender, ENTYVIO, epithelial, FABAGAL, firmly, Frankfurt, fruition, GALAFOLD, Gallen, glaucoma, grantor, Greenville, HAEGARDA, headcount, Helbing, HEMLIBRA, Hoechst, horizon, hypertension, icatibant, ICER, Idorsia, inorganic, inquiry, intolerant, intraocular, Ipsen, Iran, isolation, Johann, JP, Kala, KemPharm, KVK, Laboratoire, Lake, lanadelumab, LATAM, licence, licensor, lyophilized, malabsorption, metric, MicroHealth, Miesian, Miller, mirror, mPaCa, Munich, NAPOX, Natriuretic, navigate, noncompliance, nongovernmental, Northeastern, Novimmune, nutrition, Oregon, Orphazyme, overly, pan, Parion, PCAOB, Peptide, permeating, philosophy, PILL, platin, Plaza, portray, postretirement, prodrug, Prosecutor, Prothrombin, proud, pushing, qualification, rani, rationalization, reality, Reconsideration, Regeneron, REMICADE, repatriation, resection, reshaped, resigned, resumed, Resverlogix, retiree, RISANKIZUMAB, robust, SAHARA, SCLC, scrutinized, SECIERA, shading, sharp, Simplicity, Simplification, smooth, SOC, sodium, solidified, Spark, subsidy, subtotal, Sulzer, Sun, Sybase, Tech, tension, Teradyne, Thea, thereon, thirty, traceable, Trump, TSA, Turkey, ultra, Underscoring, underwater, undisputed, unremitted, untaxed, Van, vedolizumab, veyvondi, Vienna, Village, WAC, wean, Westlake, Wolfgang, younger
Removed:
abdominal, accelerate, accessible, accountable, ACO, acquirer, acting, agile, agreeing, amend, anorexia, APA, APRISO, ASC, Ashkenazi, Ataxia, attractive, aware, balsalazide, bioengineered, BioPharma, bp, bulimia, CAGR, CALCICHEW, Camelot, cascade, chance, CII, Clin, COLAZAL, collusion, conceal, concept, confident, consistency, constitute, converted, cooperating, Crossrow, DAYTRANA, descriptive, designing, destocking, diagram, diarrhea, Dodge, Donut, drawn, EA, EE, ELELYSO, Elizabeth, endocrine, enrolment, enterprise, Enyedy, episode, ESPP, ESTRACE, ethnic, eventually, excellent, excelling, existed, EXPUTEX, Falk, fatal, feel, ferrokin, finite, Foster, foundation, Friedreich, fulfillment, generating, grew, growing, guanfacine, guilt, HCl, history, HMV, hoc, Hole, identifying, IMS, incidence, intelligence, InterContinental, investee, Jewish, Johnson, Kappler, Korean, lean, LJ, marked, MAT, Matthew, Matthey, Medice, MEDIKINET, Meikle, methylphenidate, Ming, moving, naturally, NMO, nonalcoholic, NPA, NY, obese, OBS, occasion, optimize, override, overturned, overweight, oxidative, Palmer, Philip, Poster, practiced, predicted, Premier, prevalence, proof, prospect, Psych, purging, QUILLIVANT, racial, realistic, recommendation, recommended, rectify, redeemed, reinforce, reinvest, rejoined, relapse, remained, resubmission, retroactive, RM, Roxane, Russo, Sanfilippo, SARcode, satisfying, scale, shame, showing, Sidransky, slightly, Spada, STRATTERA, strength, subscribe, suffer, survey, sustainability, Tampa, Targacept, tendering, Theravance, Trebor, tremendously, TW, TYVENSE, underpinned, undertook, undo, unified, unknown, Victor, Wadden, Whilst, withdrew, Witt, ZFP
Filing tables
Filing exhibits
Related press release
SHPG similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements on Form S-8 (Nos. 333-09168, 333-60952, 333-91552, 333-111579, 333-129961, 333-129960, 333-202302, 333-175839, 333-165137, 333-211941, 333-222041, and 333-222044), Form S-3 (No. 333-213502) and Post-Effective Amendment No. 2 to the Registration Statement on Form S-4 (No. 333-209648) on Form S-3 of our report dated February 16, 2018, relating to the financial statements of the New Shire Income Access Share Trust appearing in this Annual Report on Form 10-K of Shire plc for the year ended December 31, 2017.
/s/ Deloitte LLP
London, United Kingdom
February 16, 2018